The 16p11 breakpoint in myxoid liposarcomas might affect the expression of the LRP gene on 16p11.2 encoding the multidrug resistance associated major vault protein

European Journal of Clinical Investigation

Volumn 30, Issue 5, 2000, Pages 447-453

  Plaat, B E C ^a,b,d   Molenaar, W M ^a,b   Sagrudny, J ^a   Bohle, R M ^a   Mastik, M F ^a,b   Hoekstra, H J ^a,b   Van Der Graaf, W T A ^a,b   Hollema, H ^a,b   Van Den Berg, E ^a,c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Justus Liebig Universität ^*  (Netherlands)

Author keywords

FUS CHOP; Liposarcoma; LRP; Major vault; t(12; 16)

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CHROMOSOME 16P; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; MYXOSARCOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 16; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSARCOMA, MYXOID; NEOPLASM PROTEINS; SOFT TISSUE NEOPLASMS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0034015366     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00640.x     Document Type: Article

References (32)

1. 1 Enzinger FM, Weiss SW. Soft Tissue Tumors. St. Louis: C.V. Mosby;1995.
2. 2 Eneroth M, Mandahl N, Heim S, Willen H, Rydholm A et al. Localization of the chromosomal breakpoints of the t (12; 16) in liposarcoma to subbands 12q13.3 and 16p11.2. Cancer Genet Cytogenet 1990;48:101-7.
3. 3 Knight JC, Renwick PJ, Dal Cin P, Van Den Berghe H, Fletcher CDM. Translocation t (12; 16) (q13; p11) in myxoid liposarcoma and round cell liposarcoma: Molecular and cytogenetic analysis. Cancer Res 1995;55:24-7.
4. 4 Fletcher CD, Akerman M, Dal Cin P, De Wever I, Mandahl N et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol 1996;148:623-30.
5. 5 Fletcher JA, Kozakewich HP, Hoffer FA, Lage JM, Weidner N et al. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med 1991;324:436-42.
6. 6 Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS. Myxoid liposarcoma: experience with chemotherapy. Cancer 1994;74:1265-9.
7. 7 Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2, 185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer soft tissue and bone sarcoma group study. J Clin Oncol 1999;17:150-7.
8. 8 van Oosterom AT, Verweij J. New drugs for the treatment of sarcomas. Hematol Oncol Clin North Am 1995;9:909-25.
9. 9 Budd GT. Palliative chemotherapy of adult soft tissue sarcomas. Semin Oncol 1995;22:30-4.
10. 10 Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469-75.
11. 11 Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowski A, Roessner A. Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas. J Cancer Res Clin Oncol 1996;122:161-5.
12. 12 Chan HS, DeBoer G, Haddad G, Ling V. Multidrug drug resistance in pediatric sarcomas. Hematol Oncol Clin North Am 1995;9:889-908.
13. 13 List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996;10:937-42.
14. 14 Leighton JC Jr, Goldstein LJ. P-glycoprotein in adult solid tumors. Expression and prognostic significance. Hematol Oncol Clin North Am 1995;9:251-73.
15. 15 Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowski A, Roessner A. Reverse transcriptasepolymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas. Diagn Mol Pathol 1996;5:98-106.
16. 16 Hunault M, Zhou D, Delmer A, Ramond S, Viguie F et al. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol 1997;74: 65-71.
17. 17 Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996;192:768-80.
18. 18 Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 1997;34:25-33.
19. 19 List AF, Spier CS, Grogan TM, Johnson C, Roe DJ er al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996;87:2464-9.
20. 20 Izquierdo MA, van der Zee AG, Vermerken JB, van der Valk P, Belien JA at al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230-7.
21. 21 Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L et al. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 1995;55: 4214-9.
22. 22 Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998;91:1508-13.
23. 23 Kuss BJ, Deeley RG, Cole SP, Willman CL, Kopecky KJ et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994;343:1531-4.
24. 24 Mitelman F. ISCN 1995: an International System for Human Cytogenetic Nomenclature. Basel: S. Karger;1995.
25. 25 Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339:237-8.
26. 26 Dei Tos AP, Piccinin S, Doglioni C, Vukosavljevic T, Mentzel T et al. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol 1997;151:1531-9.
27. 27 Panagopoulos I, Mandahl N, Mitelman F, Aman P. Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t (12; 16) and t (16; 21). Oncogene 1995;11:1133-7.
28. 28 Nakanishi H, Myoui A, Ochi T, Aozasa K. P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 1997;123:352-6.
29. 29 Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998;4:1393-403.
30. 30 Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996;148:877-87.
31. 31 Izquierdo MA, Scheffer GL, Flens MJ, van der Schroeijers ABVP, Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996;32A:979-84.
32. 32 Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995;1:578-82.